Hematologic Malignancy
Primary Cutaneous Lymphoma
CI-CAN-00003736Explore in graph →
Hematologic67 active trials10 approved drugs
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003736Explore in graph →
Clinical trials
353 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (77)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05106192 | Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT03432741 | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | terminated | Phase 1 | 17 | Mayo ClinicOTHER | 1 | May 26, 2025 | clinicaltrials |
| NCT00368784 | T Cell Repertoire Analysis of Immune Mediated Skin Diseases | completed | — | 426 | University of California, DavisOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT02548468 | Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | May 2, 2025 | clinicaltrials |
| NCT06382844 | Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL | recruiting | — | 100 | Instituto de Investigación Biomédica de SalamancaOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT03288818 | Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06914037 | A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies(COURAGE) | recruiting | Phase 1 | 24 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT02616965 | A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma | completed | Phase 1 | 16 | Fox Chase Cancer CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT02342782 | Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma | completed | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05225584 | Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors | completed | Phase 1 | 56 | Kymera Therapeutics, Inc.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04312841 | Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab | completed | Phase 2 | 6 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04072458 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | active not recruiting | Phase 1 | 30 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT06782854 | Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy | completed | — | 102 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT04774068 | Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas | completed | Phase 1 | 5 | Walter HanelOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT03385226 | A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)(PORT) | active not recruiting | Phase 2 | 46 | University College, LondonOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05333367 | MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy(MORPHEE) | recruiting | N/A | 20 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT04101331 | Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides(REDIRECT) | completed | Phase 2 | 108 | Affimed GmbHINDUSTRY | 10 | Nov 5, 2024 | clinicaltrials |
| NCT03493451 | Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms | completed | Phase 2 | 77 | BeiGeneINDUSTRY | 5 | Oct 26, 2024 | clinicaltrials |
| NCT06651203 | Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study(KISS01) | not yet recruiting | — | 460 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 21, 2024 | clinicaltrials |
| NCT05202782 | Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma | active not recruiting | Phase 2 | 24 | Northwestern UniversityOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT01460914 | Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment | completed | — | 34 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT02953301 | Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)(RESMAIN) | completed | Phase 2 | 201 | 4SC AGINDUSTRY | 12 | Aug 30, 2024 | clinicaltrials |
| NCT04676087 | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides | terminated | Phase 1 / Phase 2 | 5 | Emory UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT02192021 | Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)(MNA-D) | completed | Phase 1 | 20 | Falo, Louis, MDOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT02576496 | Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 | 106 | Mundipharma Research LimitedINDUSTRY | 7 | Jul 25, 2024 | clinicaltrials |
| NCT04014374 | Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab | recruiting | — | 150 | Kyowa Kirin, Inc.INDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT00341939 | Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data | completed | — | 484 | National Cancer Institute (NCI)NIH | 1 | Jun 13, 2024 | clinicaltrials |
| NCT06436677 | A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma(AMITY) | recruiting | — | 100 | Peking University First HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT03789864 | Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides(BDI) | terminated | N/A | 1 | Indiana UniversityOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT06421571 | The Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult Patients(GR-CTCL_CL) | unknown | — | 40 | National and Kapodistrian University of AthensOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT01226472 | Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 | completed | Phase 2 | 1 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT01728805 | Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL | completed | Phase 3 | 372 | Kyowa Kirin, Inc.INDUSTRY | 11 | Apr 25, 2024 | clinicaltrials |
| NCT04745234 | Mogamulizumab Q4week Dosing in Participants With R/R CTCL | unknown | Phase 2 | 34 | Kyowa Kirin, Inc.INDUSTRY | 5 | Apr 25, 2024 | clinicaltrials |
| NCT01588015 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT02168140 | CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | completed | Phase 1 | 16 | Wake Forest University Health SciencesOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05904522 | Histopathological Changes in Mycosis Fungoides | unknown | N/A | 10 | Bezmialem Vakif UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | terminated | Phase 1 | 3 | Stanford UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT01523223 | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies | completed | Phase 1 | 16 | Robert LowskyOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05518851 | TreAtments and outComes in paTients With prImary CutAneous Lymphoma(TACTICAL) | recruiting | — | 3,000 | Peking University First HospitalOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT00047060 | Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome | completed | Phase 1 / Phase 2 | 5 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Nov 14, 2023 | clinicaltrials |
| NCT05138458 | A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL(IMAGINE) | suspended | Phase 1 / Phase 2 | 40 | Myeloid TherapeuticsINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT04795869 | Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05329792 | L19IL2/L19TNF in Skin Cancer Patients(IntriNSiC) | unknown | Phase 2 | 70 | Philogen S.p.A.INDUSTRY | 3 | Oct 6, 2023 | clinicaltrials |
| NCT01000753 | Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma | completed | — | 174 | Children's Oncology GroupNETWORK | 4 | Oct 3, 2023 | clinicaltrials |
| NCT05781386 | A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors | unknown | Phase 1 | 255 | Jiangsu Simcere Biologics Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06037239 | Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study | unknown | Phase 1 / Phase 2 | 53 | Peking Union Medical College HospitalOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | terminated | Phase 2 | 20 | University of NebraskaOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05380635 | PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma | completed | Phase 2 | 9 | SoligenixINDUSTRY | 1 | Jun 7, 2023 | clinicaltrials |
| NCT00071071 | Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin. | completed | Phase 2 | 25 | GenmabINDUSTRY | 1 | May 18, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jun 12, 2025source: clinicaltrials